EUCTR2010-019134-27-CZ进行中（未招募）不适用
A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPY
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion, each patient must fulfill the following criteria:
- •Patients must be between the ages of 18 and 80;
- •Have diagnosed active rheumatoid arthritis according to ACR criteria functional class I-III;
- •Have at least 6 swollen joints (max = 66) and 6 tender joints (max = 68) at screening and baseline visits;
- •Patients must have at least one of the following:
- •o C-reactive protein > 1.0 mg/dl at screening;
- •o erythrocyte sedimentation rate > 28 mm/Hr;
- •Patients must have been taking methotrexate between 15 and 25 mg/week for at least 3 months and at a stable dose for at least 6 weeks;
- •Patients must be either Rheumatoid Factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) positive;
- •o Patients that are not RF or Anti-CCP positive may be entered into the study only after consultation with and approval by the Medical Monitor
- •Patients must have voluntarily signed the informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients are not eligible for this study if they fulfill one or more of the following criteria:
- •Patients who received previous therapy with any biologic agent;
- •Patients currently taking any disease modifying anti-rheumatic drug (DMARD) other than MTX;
- •o Previous non-biologic DMARD therapy is permitted as long as their last dose was at least 28 days prior to baseline;
- •Female patients of child bearing potential who are pregnant or who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner;
- •Male patients who are sexually active and not using two methods of contraception (at least one barrier: i.e. condom) with their partner;
- •Patients with any current active infection or infections requiring IV drug therapy within 30 days of baseline or oral therapy within 15 days of Baseline;
- •Patients that have had any surgical procedures within 30 days of baseline;
- •Patients with a history of HIV;
- •Patients who are Hepatitis B surface antigen positive and/or Hepatitis C antibody positive;
- •Patients who consume more than 4 units of alcohol per week (1 unit = 5 ounces/150 ml of wine = 1.5 ounces/45 ml spirits = 12 ounces/360 ml of beer);
- •Patients currently receiving any investigational drug or have received an investigational drug within 30 days of baseline or 5 half-lives of the investigational drug (whichever is longer);
- •Patients with a history of cancer within the past 5 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ;
- •Patients with a history of, or any, disease associated with an inflammatory arthritis other than RA;
- •Patients with pulmonary fibrosis (Chest x-ray must be taken within 28 days of screening);
- •Patients receiving Probenecid;
- •Patients who have received any steroid injections within 30 days of baseline;
- •Patients with concomitant diseases that are unstable (i.e. cardiac, pulmonary) or that may affect drug activity (i.e. absorption, reactions, change in kinetics);
- •Patients, in the investigator’s opinion, that have any significant renal or hepatic impairment;
- •o Patients with a serum creatinine level > 1.5 mg/dl at screening;
- •o Patients with an ALT >1.5 ULN at screening;
- •Patients considered by the investigator to be an unsuitable candidate to receive CH-4051;
- •Wheelchair or bed-bound patients.
研究者
相似试验
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPYRhuematoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019134-27-BGChelsea Therapeutics, Inc250
进行中（未招募）
1 期
A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WITH ADVANCED BILIARY TRACT CANCER (GALLBLADDER CANCER, CANCER OF THE EXTRAHEPATIC BILE DUCT, INTRAHEPATIC CHOLANGIOCARCINOMA AND AMPULLARY CARCINOMA) - VANGOGHADVANCED BILIARY TRACT CANCERMedDRA version: 9.1Level: HLGTClassification code 10019815Term: Hepatobiliary neoplasms malignant and unspecifiedEUCTR2007-003056-12-ITASTRAZENECA174
进行中（未招募）
1 期
A Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 Compared with Placebo in Participants with Facioscapulohumeral Muscular DystrophyFacioscapulohumeral muscular dystrophy (FSHD)EUCTR2021-006255-34-DKF.Hoffmann-La Roche Ltd48
进行中（未招募）
1 期
A Study of MOXR0916 in Combination with Atezolizumab versus Atezolizumab Alone in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma who are Ineligible for Cisplatin-Based TherapyAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 19.1Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2016-004165-58-FRGenentech, Inc5
进行中（未招募）
1 期
A Study of MOXR0916 in Combination with Atezolizumab versus Atezolizumab Alone in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma who are Ineligible for Cisplatin-Based TherapyAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 19.1 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864EUCTR2016-004165-58-PTGenentech, Inc5